13.33
Precedente Chiudi:
$14.10
Aprire:
$14.1
Volume 24 ore:
220.45K
Relative Volume:
2.35
Capitalizzazione di mercato:
$192.96M
Reddito:
$1.80M
Utile/perdita netta:
$1.76B
Rapporto P/E:
0.1123
EPS:
118.674
Flusso di cassa netto:
$-149.23M
1 W Prestazione:
-6.91%
1M Prestazione:
-1.84%
6M Prestazione:
-10.42%
1 anno Prestazione:
-62.00%
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Confronta INBX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
INBX
Inhibrx Biosciences Inc
|
13.33 | 192.96M | 1.80M | 1.76B | -149.23M | 118.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2022-03-16 | Iniziato | SMBC Nikko | Outperform |
2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2020-09-14 | Iniziato | Credit Suisse | Outperform |
2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
How the (INBX) price action is used to our Advantage - Stock Traders Daily
JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India
Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo
Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit - Stock Titan
Long Term Trading Analysis for (INBX) - Stock Traders Daily
When (INBX) Moves Investors should Listen - Stock Traders Daily
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
When the Price of (INBX) Talks, People Listen - Stock Traders Daily
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com
(INBX) Trading Signals - Stock Traders Daily
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times
Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial - Stock Titan
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront - Stock Titan
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India
(INBX) Trading Report - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - News & Insights
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartzy
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartzy
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times
James Sabry on industry-shaping changes in innovation and deal-making - BioCentury
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):